Home »
India Pharmaceuticals and Healthcare Report Q2 2011

India Pharmaceuticals and Healthcare Report Q2 2011

Double click on above image to view full picture

Email to a Colleague - Print - Fax Order

Additional Information

Price	$530.00
Publisher	Business Monitor International
Date of Report	Apr 8, 2011

Add to Wishlist | Add to Compare

Qty:

-OR-

Quick Overview

BMI View: India's pharmaceutical market beguiles multinational pharmaceutical companies. Sales of medicines are booming and red tape will prevent systematic price cuts, which is a nascent trend in developing countries. A rapidly increasing prevalence of non-communicable diseases, such as hypertension, diabetes and cardiovascular conditions, also appeals to foreign firms and their product portfolios of medicines targeting chronic illnesses. However, India's intellectual property regime fails to acknowledge incremental innovation, discouraging many multinationals from launching products or making fixed capital investments.
Headline Expenditure Projections
?? Pharmaceuticals: INR862.48bn (US$18.81bn) in 2010 to INR1,008bn (US$21.72bn) in 2011; +16.9% in local currency terms and +15.5% in US dollar terms. Our forecast has been revised up moderately from Q111 due to analyst intervention.
?? Healthcare: INR2,699bn (US$58.85bn) in 2010 to INR2,956bn (US$63.70bn) in 2011; +9.5% in local currency terms and +8.2% in US dollar terms. Our forecast has been revised up moderately from Q111 due to analyst intervention.
?? Medical devices: INR132.43bn (US$2.89bn) in 2010 to INR152.31bn (US$3.28bn) in 2011; +12.3% in local currency terms and +16.3% in US dollar terms. Our forecast has been revised down moderately from Q111 due to analyst intervention.
Business Environment Rating: India is underperforming and scores only 56.0 (unchanged from Q111). Despite a rapidly expanding pharmaceutical market, the country remained in ninth position in the 17- country Asia Pacific region. A key drawback is its Country Rewards score, which at 43 is well below the regional average of 55. This category assesses India's pensionable population, rate of urbanisation and population growth.
Key Trends & Developments
?? GlaxoSmithKline (GSK) hopes to outpace the market in 2011 after underperforming in 2010, according to Mehernosh Kapadia, senior executive director, in February 2011. To achieve this goal, GSK will launch new patented and branded generic drugs and expand its sales and marketing network.
?? Despite growing domestic resistance to acquisitions of local pharmaceutical companies by foreign firms, UK-based household products giant Reckitt Benckiser said it would acquire India's Paras Pharmaceuticals for INR32.6bn (US$724mn) in December 2010.
BMI Economic View: India undoubtedly enjoys many of the structural ingredients for rapid growth. However, we suspect that a sense of complacency is taking root amongst policymakers and investors regarding the economy's near-term prospects. From our perspective, the triple threat of higher crude prices, stubborn core inflation, and concerns over governance has raised questions marks over the durability of domestic demand. For these reasons, we are comfortable remaining well below consensus on FY2011/12 (Apr-Mar) growth at 7.8%.
BMI Political View: Recent corruption scandals, a cabinet shake-up and a social-leaning budget have highlighted the growing divisions between the reformists and populists within India's United Progressive Alliance (UPA). Prime Minister Manmohan Singh's position has weakened significantly, and we cannot rule out high-level government changes should the dominant Indian National Congress (INC) and its allies fare poorly in the key state elections of Tamil Nadu (due May 2011) and West Bengal (June 2011).

Table of Contents

Executive Summary ........................................................................................................................................ 5
SWOT Analysis ................................................................................................................................................ 7
India Pharmaceutical Industry SWOT .................................................................................................................................................................. 7
Political SWOT ..................................................................................................................................................................................................... 8
Economic SWOT ................................................................................................................................................................................................... 9
Business Environment SWOT .............................................................................................................................................................................. 10
India’s Pharmaceutical Business Environment Ratings ............................................................................ 11
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q211 ................................................................................................... 11
Rewards .............................................................................................................................................................................................................. 12
Risks ................................................................................................................................................................................................................... 12
India – Market Summary ............................................................................................................................... 13
Regulatory Environment............................................................................................................................... 14
Table: Responsibilities Of India’s Department Of Pharmaceuticals................................................................................................................... 15
Pharmaceutical Advertising ................................................................................................................................................................................ 16
Pharmacovigilance ............................................................................................................................................................................................. 16
IP Regime ........................................................................................................................................................................................................... 17
Table: History Of The Indian Patent System ....................................................................................................................................................... 18
Patent Disputes ................................................................................................................................................................................................... 19
Counterfeit Medicines ......................................................................................................................................................................................... 20
Pricing And Reimbursement ............................................................................................................................................................................... 21
Industry Trends And Developments ............................................................................................................ 23
Epidemiology ...................................................................................................................................................................................................... 23
Healthcare Sector ............................................................................................................................................................................................... 25
Healthcare Funding ............................................................................................................................................................................................ 27
Healthcare Insurance ......................................................................................................................................................................................... 27
Research And Development ................................................................................................................................................................................ 28
Clinical Trials ..................................................................................................................................................................................................... 29
Recent Developments In The Clinical Trials Industry ......................................................................................................................................... 30
Active Pharmaceutical Ingredients ..................................................................................................................................................................... 30
Biotechnology Sector .......................................................................................................................................................................................... 32
Traditional Medicines ......................................................................................................................................................................................... 33
Industry Forecast Scenario ........................................................................................................................... 34
Overall Market Forecast..................................................................................................................................................................................... 34
Table: Pharmaceutical Sales Indicators 2007-2015 ........................................................................................................................................... 35
Key Growth Factors – Industry........................................................................................................................................................................... 36
Table: Health Expenditure Indicators 2007-2015 ............................................................................................................................................... 37
Key Growth Factors – Macroeconomic .............................................................................................................................................................. 38
Table: India - Economic Activity; 2006-2015 ..................................................................................................................................................... 42
Prescription Drug Market Forecast .................................................................................................................................................................... 43
Table: Prescription Drug Sales Indicators 2007-2015 ....................................................................................................................................... 44
Patented Drug Market Forecast ......................................................................................................................................................................... 45
Table: Patented Drug Sales Indicators 2007-2015 ............................................................................................................................................. 46
Generic Drug Market Forecast ........................................................................................................................................................................... 47
Table: Generic Drug Sales Indicators 2007-2015 .............................................................................................................................................. 48
OTC Medicine Market Forecast ......................................................................................................................................................................... 49
Table: OTC Medicine Sales Indicators 2007-2015 ............................................................................................................................................. 50
Pharmaceutical Trade Forecast ......................................................................................................................................................................... 51
Table: Pharmaceutical Imports & Exports Indicators 2007-2015 ...................................................................................................................... 53
Medical Device Market Forecast ........................................................................................................................................................................ 54
Table: Medical Device Sales Indicators 2007-2015............................................................................................................................................ 55
Other Healthcare Data Forecasts ....................................................................................................................................................................... 56
Key Risks To BMI’s Forecast Scenario ............................................................................................................................................................... 56
Competitive Landscape ................................................................................................................................ 58
Top 25 Pharmaceutical Companies According To Sales In India ........................................................................................................................ 59
Key Pharmaceutical Industry Developments ...................................................................................................................................................... 60
Company Profiles .......................................................................................................................................... 61
Leading Domestic Manufacturers ....................................................................................................................................................................... 61
Cipla ................................................................................................................................................................................................................... 61
Ranbaxy Laboratories ......................................................................................................................................................................................... 64
Dr Reddy’s Laboratories .................................................................................................................................................................................... 67
Aurobindo Pharmaceutical ................................................................................................................................................................................. 69
Venus Remedies .................................................................................................................................................................................................. 71
Granules India .................................................................................................................................................................................................... 73
Piramal Healthcare ............................................................................................................................................................................................ 75
Zydus Cadila ....................................................................................................................................................................................................... 77
Leading Multinational Manufacturers ..................................................................................................................................................................... 79
Pfizer .................................................................................................................................................................................................................. 79
GlaxoSmithKline (GSK) ...................................................................................................................................................................................... 82
Novartis .............................................................................................................................................................................................................. 85
Sanofi-Aventis ..................................................................................................................................................................................................... 87
Merck & Co ........................................................................................................................................................................................................ 90
Country Snapshot: India Demographic Data............................................................................................... 92
Section 1: Population .......................................................................................................................................................................................... 92
Table: Demographic Indicators, 2005-2030 ....................................................................................................................................................... 92
Table: Rural/Urban Breakdown, 2005-2030 ...................................................................................................................................................... 93
Section 2: Education and Healthcare ................................................................................................................................................................. 93
Table: Education, 2002-2005 ............................................................................................................................................................................. 93
Table: Vital Statistics, 2005-2030 ....................................................................................................................................................................... 93
Section 3: Labour Market And Spending Power ................................................................................................................................................. 94
Table: Employment Indicators,1996-2001 .......................................................................................................................................................... 94
Table: Consumer Expenditure, 2000-2012 (US$) ............................................................................................................................................... 94
Table: Average Annual Manufacturing Wages, 2000-2012 ................................................................................................................................ 95
BMI Methodology .......................................................................................................................................... 96
How We Generate Our Pharmaceutical Industry Forecasts ............................................................................................................................... 96
Pharmaceuticals Business Environment Ratings ................................................................................................................................................ 97
Risk/Reward Ratings Methodology ..................................................................................................................................................................... 97
Ratings Overview ................................................................................................................................................................................................ 97
Table: Pharmaceutical Business Environment Indicators .................................................................................................................................. 98
Weighting ............................................................................................................................................................................................................ 99
Table: Weighting Of Components ....................................................................................................................................................................... 99
Sources ............................................................................................................................................................................................................... 99